UB-621 / United BioPharma - LARVOL DELTA

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: United BioPharma | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Infectious Disease

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: UBP Greater China (Shanghai) Co., Ltd | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Infectious Disease

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals (clinicaltrials.gov) - P2 | N=44 | Not yet recruiting | Sponsor: UBP Greater China (Shanghai) Co., Ltd | Trial completion date: Jan 2023 ➔ Jan 2025 | Trial primary completion date: Oct 2022 ➔ Oct 2024

Trial completion date • Trial primary completion date • Herpes Simplex • Infectious Disease

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes (clinicaltrials.gov) - P2; N=200; Not yet recruiting; Sponsor: UBP Greater China (Shanghai) Co., Ltd

New P2 trial • Infectious Disease